TABLE 1.

Participant characteristics (n=1381)

Clinical Characteristics	mean [SD] or n [%]
Age (years)	59 [8]
Females – n [%]	712 [51.6]
Body mass index (kg/m2)	28.1 [5.2]
Triglycerides (mg/dL)	135 [86]
Waist circumference (cm)	39.1 [5.5]
Alcohol use (oz/month)	139 [289]
Smoking -n [%]	173 [12.5]
Diabetes - n [%]	159 [11.5]
Hypertension -n [%]	584 [42.3]
Post-menopausal - n [%]	593 [83.4]
Hormone replacement therapy (post-menopausal) - n [%]	239 [33.6]
Lipid lowering treatment - n [%]	283 [20.5]
Osteoporosis treatment n [%]	86 [6.2]
Prevalent cardiovascular disease n [%])	161 [11.7]

Vitamin K status	mean [SD]	minimum-maximum
Plasma phylloquinone (nmol/L)	1.5 [1.9]	0.1-25.6
Percent undercarboxylated osteocalcin	17.4 [16.8]	0-79.7
Phylloquinone intake (μg/d)	156 [118]	17-2059
Vitamin D status
Plasma 25 (OH)D (nmol/L)	49.4 [18.6]	5.5-146.3
Vitamin D intake (IU/d)	426 [317]	23-2589
Measures of Inflammation
Inflammation Summary Statistic	−0.3 [4.9]	−12.1-28.4
CD40 ligand (ng/mL)	3.4 [4.8]	0.1-29.5
C-reactive protein (mg/L)	3.8 [5.3]	0.2-66.2
Fibrinogen (mg/dl)	375 [71]	181-676
Intercellular adhesion molecule-1 (mg/mL)	259 [83]	130-1328
Interleukin-6 (pg/mL)	3.6 [3.8]	0.4-51.2
Lipoprotein phospholipase A2 activity (nmol/mL/min)	144 [36]	41-364
Lipoprotein phospholipase A2 mass (ng/mL)	302 [95]	78-886
Monocyte chemoattractant protein (pg/mL)	322 [121]	31-2140
Myeloperoxidase (mg/mL)	47.9 [32.5]	4.9-377.0
Osteoprotegerin (pmol/L)	5.5 [1.8]	0.6-26.9
P-selectin (ng/mL)	36.1 [14.1]	2.5-175.8
Tumor necrosis factor-α (pg/mL)	1.4 [1.3]	0.3-21.1
Tumor necrosis factor receptor-2 (pg/mL)	2158[769]	892-8215
Urinary isoprostanes (pg/mL)	1559 [1369]	31-11125